ARTL - Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany | Benzinga
SOLANA BEACH, Calif., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced new preclinical data on ART12.11, the Company's proprietary cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP), was presented at the 4th Annual Med-Cannabis 2023 conference today, December 5, 2023 in Frankfurt, Germany.
During the talk, "A novel cannabidiol:tetramethylpyrazine cocrystal improves the bioavailability and efficacy of CBD," presented by George Warren, PhD., Principal Scientist at Artelo Biosciences, new data on ART12.11 demonstrating improved CBD bioavailability in both the fed and fasted states compared to CBD alone was discussed. The presentation included results from additional preclinical studies that demonstrated greater anxiolytic, anti-depressive, and pro-social effects of ART12.11 compared to CBD alone.
"ART12.11's improved physiochemical properties continues to differentiate it from CBD alone," commented Professor Saoirse O'Sullivan, Vice President of Translational Science at Artelo Biosciences. "The therapeutic utility of CBD is hampered by its physical properties, including high lipophilicity, poor solubility and stability, as well as poor oral bioavailability. In contrast, ART12.11 demonstrated greater bioavailability in both the fed and fasted states, as now observed in multiple preclinical studies with two ...